

Copy file

L20 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 2001:119741 CAPLUS
DN 135:102738
TI Anticatabolism after severe **burn**: synergism between growth hormone and propranolol
AU Hart, David W.; Wolf, Steven E.; Lal, Sofia; Obeng, Michael; Wolfe, Robert R.; Herndon, David N.
CS Department of Surgery, The University of Texas Medical Branch and Shriners Hospitals for Children, Galveston, TX, USA
SO Surg. Forum (2000), 51, 196-197
CODEN: SUFOAX; ISSN: 0071-8041
PB American College of Surgeons
DT Journal
LA English
CC 2-5 (Mammalian Hormones)
Section cross-reference(s): 1
AB The catecholamine-mediated hypermetabolic response to severe **burn** is assocd. with exaggerated muscle protein catabolism. Recombinant human growth hormone (rhGH) has been shown to improve net muscle protein synthesis in **burn** patients. Long-term .beta. blockade decreases the elevated resting energy expenditure assocd. with hypermetabolism. A study was conducted to test the hypothesis that the addn. of propranolol to growth hormone will synergistically improve muscle protein kinetics after **burn**. Results indicated that in severely **burned** pediatric patients, the therapeutic combination of rhGH with antagonism of catecholamines by .beta. blockade attenuates hypermetabolism and reverses muscle protein catabolism.
ST anticatabolism severe **burn** synergism growth hormone propranolol
IT Development, mammalian postnatal
(child; synergism between growth hormone and propranolol in anticatabolism after severe **burn** in human pediatric patients)
IT **Burn**
Energy metabolism, animal
Muscle
Protein degradation
Translation, genetic
(synergism between growth hormone and propranolol in anticatabolism after severe **burn** in human pediatric patients)
IT Adrenoceptor antagonists
(.beta.-; synergism between growth hormone and propranolol in anticatabolism after severe **burn** in human pediatric patients)
IT 525-66-6, Propranolol 9002-72-6, Growth hormone
RL: BAC (Biological activity or effector, except adverse); **THU** (**Therapeutic use**); BIOL (Biological study); USES (Uses)
(synergism between growth hormone and propranolol in anticatabolism after severe **burn** in human pediatric patients)
RE.CNT 2
RE
(1) Breitenstein, E; Burns 1990, V16, P259 MEDLINE
(2) Gore, D; Arch Surg 1991, V126, P38 MEDLINE

L28 ANSWER 3 OF 4 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 3
 AN 94373257 EMBASE
 DN 1994373257
 TI Lipolysis in burned patients is stimulated by the .beta.2-receptor for catecholamines.
 AU Herndon D.N.; Nguyen T.T.; Wolfe R.R.; Maggi S.P.; Biolo G.; Muller M.; Barrow R.E.; Forse R.A.; Bessey P.Q.
 CS Burns Institute, Shriners Hosp. for Crippled Children, 815 Market St, Galveston, TX 77550-2725, United States
 SO Archives of Surgery, (1994) 129/12 (1301-1305).
 ISSN: 0004-0010 CODEN: ARSUAX
 CY United States
 DT Journal; Article
 FS 009 Surgery
 037 Drug Literature Index
 LA English
 SL English
 AB Objective: To determine if the cardiovascular effects of excessive catecholamines could be selectively blocked in severely **burned** patients without adversely affecting protein or fat kinetics. Design: Prospective cohort study. Setting: A large tertiary care referral center in Galveston, Tex. Patients: Sixteen patients with greater than 40% body surface area **burns**. Interventions: Patients were randomly selected to receive **propranolol** hydrochloride, a nonselective .beta.1- and .beta.2-blocker, or metoprolol tartrate, a selective .beta.1-blocker. Main Outcome Measures: Heart rate; rate-pressure product; rate of appearance of urea, glucose, and leucine; and leucine oxidation were measured before and after selective or nonselective .beta.-adrenergic blockade. Results: **Propranolol** and metoprolol caused a significant decrease in heart rate, from a mean (.-.SD) of 143.-.15 to 115.-.11 and from 147.-.17 to 120.-.9 beats per minute, respectively, during the 5-day study period. Neither the rate of appearance of urea nor the rate of urea production were significantly altered by **propranolol** or metoprolol therapy. Only **propranolol** produced a significant decrease (P<.05) in the rate of appearance of glycerol, from a mean (.-.SD) of 5.54.-.0.62 to 3.07.-.0.7 .mu.mol/kg per minute. The rate of appearance of leucine, used as an index of total body protein **catabolism**, was not significantly altered by either .beta.- blocker. Conclusions: Selective .beta.1-adrenergic blockade did not reduce lipolysis; however, a .beta.1- and .beta.2-adrenergic blockade significantly reduced lipolysis. Thus, the increased lipolysis, characteristic of severely **burned** patients, is caused by stimulation of the .beta.2-adrenergic receptors for catecholamines.
 CT Medical Descriptors:
 *burn: TH, therapy
 *lipolysis
 amino acid metabolism
 article
 cardiovascular effect
 catecholamine release
 clinical article
 clinical trial
 drug effect
 drug selectivity
 heart rate
 human
 intravenous drug administration
 isotope labeling
 metabolic parameters
 priority journal
 protein degradation
 thermal injury: TH, therapy
 urea cycle
 Drug Descriptors:
 *beta 2 adrenergic receptor
 beta 1 adrenergic receptor
 *beta 1 adrenergic receptor blocking agent: CT, clinical trial
 *beta 1 adrenergic receptor blocking agent: AD, drug administration


```

=> s propranolol/cn
L1      1 PROPRANOLOL/CN

=> d

L1      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN      525-66-6  REGISTRY
CN      2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (9CI)  (CA
      INDEX NAME)
OTHER CA INDEX NAMES:
CN      2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)- (7CI, 8CI)
OTHER NAMES:
CN      (.+-.)-Propranolol
CN      .beta.-Propranolol
CN      1-(1-Naphthyloxy)-3-(isopropylamino)-2-propanol
CN      1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
CN      AY 64043
CN      Betalong
CN      dl-Propranolol
CN      DL-Propranolol
CN      Propranolol
CN      Proprasylyt
CN      Racemic propranolol
CN      Reducor
FS      3D CONCORD
DR      13013-17-7
MF      C16 H21 N O2
CI      COM
LC      STN Files:  ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
      BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN,
      CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSNB, DDFU, DIOGENES, DRUGPAT,
      DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*,
      NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER,
      TOXLIT, ULIDAT, USAN, USPATFULL, VETU
      (*File contains numerically searchable property data)
Other Sources:  EINECS**, WHO
      (**Enter CHEMLIST File for up-to-date regulatory information)

```



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

```

      8905 REFERENCES IN FILE CA (1967 TO DATE)
      102 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
      8914 REFERENCES IN FILE CAPLUS (1967 TO DATE)
      1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```

```

=> s timolol/cn
L2      1 TIMOLOL/CN

```

=> d


```

L2      ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2001 ACS
RN      26839-75-8  REGISTRY
CN      2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-
      thiadiazol-3-yl]oxy]-, (2S)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:

```

CN 1;2,5-Thiadiazole, 2-propanol deriv.
 CN 2-Propanol, 1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-, (S)-(-)- (8CI)
 CN 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-
 OTHER NAMES:
 CN (-)-S-Timolol
 CN (-)-Timolol
 CN (S)-Timolol
 CN L-Timolol
 CN l-Timolol
 CN Oftensin
 CN **Timolol**
 FS STEREOSEARCH
 DR 131628-37-0, 194288-09-0
 MF C13 H24 N4 O3 S
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, SPECINFO, TOXCENTER, TOXLIT, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, NDSL**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1022 REFERENCES IN FILE CA (1967 TO DATE)
 16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1023 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> s nadolol/cn
 L3 1 NADOLOL/CN

=> d

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
 RN 42200-33-9 REGISTRY
 CN 2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN **Nadolol**
 CN SQ 11725
 FS 3D CONCORD
 MF C17 H27 N O4
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TOXLIT, ULIDAT, USAN, USPATFULL
 (*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

614 REFERENCES IN FILE CA (1967 TO DATE)

10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

616 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s atenolol/cn

L4 1 ATENOLOL/CN

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 29122-68-7 REGISTRY

CN Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy] - (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Acetamide, 2-[p-[2-hydroxy-3-(isopropylamino)propoxy]phenyl] - (8CI)

OTHER NAMES:

CN (.+-.)-Atenolol

CN (RS)-Atenolol

CN **Atenolol**

CN DL-Atenolol

CN dl-Atenolol

CN Duraatenolol

CN ICI 66082

CN Tenormin

FS 3D CONCORD

DR 106020-65-9, 60966-51-0

MF C14 H22 N2 O3


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2255 REFERENCES IN FILE CA (1967 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2262 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s metoprolol/cn
L5 1 METOPROLOL/CN

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 51384-51-1 REGISTRY
CN 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]- (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN (.+-.)-Metoprolol
CN (RS)-Metoprolol
CN 1-Isopropylamino-3-[4-(2-methoxyethyl)phenoxy]-2-propanol
CN Beatrolol
CN Beloc-Zok
CN CGP 2175
CN dl-Metoprolol
CN **Metoprolol**
CN Spesicor
FS 3D CONCORD
DR 54163-88-1, 37350-58-6
MF C15 H25 N O3
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,
CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB,
IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PHARMASEARCH,
PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, ULIDAT, USAN, USPATFULL,
VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


649 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
654 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s esmolol/cn
L6 1 ESMOLOL/CN

=> d

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 81147-92-4 REGISTRY
CN Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (.+-.)-Esmolol

CN ASL 8052-001
 CN Brevibloc
 CN **Esmolol**
 FS 3D CONCORD
 DR 103598-03-4, 84057-94-3
 MF C16 H25 N O4
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DIOGENES, DRUGPAT,
 DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB, IFIUDb, IPA, MEDLINE, MRCK*,
 PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

161 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 162 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> s nipradilol/cn
 L7 1 NIPRADILOL/CN

=> d

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
 RN 81486-22-8 REGISTRY
 CN 2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Hypadil
 CN K 351
 CN KT 210
 CN **Nipradilol**
 FS 3D CONCORD
 MF C15 H22 N2 O6
 CI COM
 LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, DDFU, DRUGPAT, DRUGU,
 EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER,
 TOXLIT, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

152 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
153 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s carvedilol/cn
L8 1 CARVEDILOL/CN

=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
RN 72956-09-3 REGISTRY
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN (.+-.)-Carvedilol

CN BM 14190

CN **Carvedilol**

CN Coreg

CN DQ 2466

CN SKF 105517

FS 3D CONCORD

DR 107741-96-8

MF C24 H26 N2 O4


CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN,
CIN, CSCHM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*,
SYNTHLINE, TOXCENTER, TOXLIT, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

503 REFERENCES IN FILE CA (1967 TO DATE)
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 513 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> s acebutolol/cn
 L9 1 ACEBUTOLOL/CN

=> d

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
 RN 37517-30-9 REGISTRY
 CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (.+-.)-
 OTHER NAMES:
 CN (.+-.)-Acebutolol
 CN **Acebutolol**
 CN dl-Acebutolol
 CN Neptal
 FS 3D CONCORD
 DR 28197-63-9
 MF C18 H28 N2 O4
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, TOXLIT, USAN, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

749 REFERENCES IN FILE CA (1967 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 750 REFERENCES IN FILE CAPLUS (1967 TO DATE)